论文部分内容阅读
目的探讨丹参注射液联合酒石酸美托洛尔对不稳定型心绞痛(UAP)患者的影响。方法选取2015年4月—2017年3月陕西省第二人民医院收治的UAP患者95例,采用随机数字表法分为对照组(n=47)和观察组(n=48)。对照组患者予以酒石酸美托洛尔治疗,而观察组患者在对照组基础上予以丹参注射液治疗;两组患者均持续治疗4周。比较两组患者临床疗效,治疗前后血清可溶性细胞间黏附分子1(s ICAM-1)及基质金属蛋白酶9(MMP-9)水平、生活质量(QOL),治疗期间不良反应发生情况。结果观察组患者总有效率高于对照组(P<0.05)。治疗前两组血清s ICAM-1、MMP-9水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清s ICAM-1、MMP-9水平低于对照组(P<0.05)。治疗前两组患者QOL评分比较,差异无统计学意义(P>0.05);治疗后观察组患者QOL评分高于对照组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论丹参注射液联合酒石酸美托洛尔治疗UAP的临床疗效确切,可有效降低血清s ICAM-1、MMP-9水平,改善患者生活质量,且安全性较高。
Objective To investigate the effect of Salvia miltiorrhiza injection combined with metoprolol tartrate on patients with unstable angina pectoris (UAP). Methods A total of 95 UAP patients admitted to the Second People’s Hospital of Shaanxi Province from April 2015 to March 2017 were randomly divided into control group (n = 47) and observation group (n = 48). Patients in the control group were treated with metoprolol tartrate, while patients in the observation group were treated with Salvia miltiorrhiza injection on the basis of the control group. Patients in both groups were treated for 4 weeks. The clinical efficacy, serum ICAM-1 and MMP-9 levels, quality of life (QOL), and adverse reactions during the treatment were compared between the two groups. Results The total effective rate in observation group was higher than that in control group (P <0.05). The levels of serum ICAM-1 and MMP-9 in the two groups before treatment were significantly lower than those in the control group after treatment (P <0.05) ). There was no significant difference in QOL scores between the two groups before treatment (P> 0.05). After treatment, the QOL score of the observation group was higher than that of the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P> 0.05). Conclusion Danshen injection combined with metoprolol tartrate in the treatment of UAP has definite clinical curative effect, which can effectively reduce the serum levels of s ICAM-1 and MMP-9 and improve the quality of life of patients with high safety.